• Medios completed the acquisition of a 74% stake in Caesar & Loretz (Caelo) on Oct. 1, 2026.
• Options were agreed to buy the remaining 26% stake.
• Deal positions Medios as Germany’s market leader in active pharmaceutical ingredients for pharmacies and hospitals.
• Caelo is expected to generate about EUR 40 million in revenue in the current financial year.
• Caelo will remain branded independently, serving as the German anchor for a European network with Magis Pharma and Metapharmaceutical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medios AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2408342_en) on October 01, 2026, and is solely responsible for the information contained therein.